Artivion, Inc.
NYSE•AORT
CEO: Mr. James Patrick Mackin
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1993-02-12
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Contact Information
Market Cap
$1.72B
P/E (TTM)
175.1
34.2
Dividend Yield
--
52W High
$48.25
52W Low
$21.97
52W Range
Rank59Top 87.6%
2.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$115.99M+0.00%
4-Quarter Trend
EPS
$0.05+0.00%
4-Quarter Trend
FCF
-$7.95M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Total Revenue Increased 14% Total revenues reached $441.33M USD in 2025, showing a 14% increase compared to the prior year.
Achieved Net Income Reported net income of $9.77M USD for 2025, successfully reversing the $13.36M net loss from 2024.
Aortic Stent Grafts Growth Aortic stent graft sales increased 29% to $159.37M USD, primarily driven by higher unit volumes sold globally.
Strong Operating Cash Flow Net cash provided by operating activities totaled $39.88M USD in 2025, supporting liquidity and capital needs.
Risk Factors
Supply Chain Single Source Reliance Reliance on single or sole-source suppliers limits negotiation power and risks manufacturing cessation upon disruption.
CryoValve Reclassification Risk Potential FDA reclassification of CryoValve SGPV to Class III device may render continued processing commercially infeasible.
International Economic Headwinds Geopolitical conflicts and inflation increase supply chain costs and negatively impact foreign currency denominated revenues.
Cybersecurity Incident Impact The 2024 cybersecurity incident resulted in a $4.3M impact on 2025 results, highlighting ongoing IT security risks.
Outlook
AMDS US Approval Pursuit Pivotal trial enrollment for AMDS completed; seeking FDA PMA approval anticipated in mid-2026.
Growth Strategy Focus Areas Strategic plan centers on new products, new indications, global expansion into China/Brazil, and business development.
NEXUS ONE PMA Anticipated Endospan anticipates receiving FDA PMA approval for NEXUS ONE in 2026, strengthening the aortic stent graft portfolio.
BioGlue China Commercialization BioGlue commercialization in China commenced during the first half of 2025 following NMPA regulatory approval in 2024.
Peer Comparison
Revenue (TTM)
$6.32B
$3.12B
$2.29B
Gross Margin (Latest Quarter)
165.5%
101.7%
96.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| COGT | $5.95B | -7.5 | -100.2% | 27.0% |
| BKD | $3.41B | -12.8 | -523.8% | 112.0% |
| LQDA | $3.38B | -49.1 | -209.3% | 60.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.4%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow
Deep Research
Next earnings:May 4, 2026
EPS:$0.03
|Revenue:$115.78M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data